Recruiting

Angiotensin II

Sponsor:

Brett A Faine

Code:

NCT06693726

Conditions

Septic Shock

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

Angiotensin II Infusion

Study Details

Brief summary:

This pilot study will enroll 20 patients with septic shock and require emergent vasopressor support in the emergency department (ED). The primary objective of the study is to determine the feasibility of early peripheral administration of angiotensin II for treatment of septic shock in the ED

Conditions

Septic Shock

Study ID

NCT06693726

Start date

Apr 1, 2025

Status verified date

Sep, 2026

Completion date

Jan 30, 2027

Anticipated

Primary completion date

Dec 31, 2026

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Inclusion Criteria

1. Age ≥18; and
2. Requiring norepinephrine at a dose of 0.05-0.25 mcg/kg/min mcg/kg/minute despite adequate fluid resuscitation; and
3. Receiving intravenous antibiotics or clinician's intention to administer antibiotics at the time of enrollment; and
4. Can provide written informed consent (or legally authorized representative).

Exclusion Criteria

1. Acute coronary syndrome;
2. Cardiogenic shock;
3. Patients with a history of mesenteric ischemia;
4. Patients with a history of having an aortic dissection or abdominal aortic aneurysm;
5. Patients with an expected lifespan of <12 hours;
6. Patients with hemorrhagic shock (e.g., actively receiving transfusion of packed red blood cells);
7. Active administration of two vasoactive agents before enrollment; and
8. Pre-existing thromboembolic disease or inability to tolerate pharmacologic VTE prophylaxis.

Study Design

Enrollment

20 participants

Anticipated

Allocation

Non randomized

Intervention Model

Single group

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Angiotensin II Infusion

Interventions

Angiotensin II Infusion

Angiotensin II continuous infusion

Primary outcome measure

  • Feasibility of completing all clinical trial activities [ Time Frame: From enrollment to the end of treatment up to 6 hours after the angiotensin II infusion is initiated ]

Central Contacts and Locations

Central contacts

Locations

University of Iowa Hospitals and Clinics

Recruiting

Iowa City, Iowa, United States, 52242

Contacts

More Information

Sponsor

Brett A Faine

Last update posted

Sep 2, 2026

Last verified

Sep, 2026

Keywords

  • Angiotensin II

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by Brett A Faine on 2026-09-02.